Analysts Set OptimizeRx Co. (NASDAQ:OPRX) PT at $9.06

OptimizeRx Co. (NASDAQ:OPRX) has been given an average rating of “Moderate Buy” by the nine ratings firms that are covering the stock, MarketBeat Ratings reports. Three analysts have rated the stock with a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the company. The average 12-month target price among brokerages that have issued ratings on the stock in the last year is $9.06.

Several equities analysts have recently commented on the stock. JMP Securities restated a “market outperform” rating and issued a $8.00 target price on shares of OptimizeRx in a research report on Thursday, February 6th. B. Riley raised OptimizeRx to a “strong-buy” rating in a report on Wednesday, March 12th.

Insider Activity at OptimizeRx

In related news, Director James Paul Lang purchased 321,408 shares of the firm’s stock in a transaction that occurred on Friday, March 14th. The stock was acquired at an average price of $7.60 per share, for a total transaction of $2,442,700.80. Following the completion of the acquisition, the director now owns 389,452 shares of the company’s stock, valued at $2,959,835.20. This represents a 472.35 % increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. 6.10% of the stock is currently owned by insiders.

Institutional Trading of OptimizeRx

A number of hedge funds have recently bought and sold shares of the business. Bank of New York Mellon Corp grew its holdings in OptimizeRx by 2.1% during the first quarter. Bank of New York Mellon Corp now owns 89,538 shares of the company’s stock valued at $775,000 after purchasing an additional 1,826 shares during the period. Rhumbline Advisers boosted its stake in OptimizeRx by 10.5% in the 1st quarter. Rhumbline Advisers now owns 27,785 shares of the company’s stock worth $241,000 after purchasing an additional 2,636 shares during the period. Wells Fargo & Company MN lifted its holdings in shares of OptimizeRx by 33.3% in the fourth quarter. Wells Fargo & Company MN now owns 11,208 shares of the company’s stock worth $54,000 after buying an additional 2,797 shares in the last quarter. Barclays PLC boosted its holdings in OptimizeRx by 13.5% in the 4th quarter. Barclays PLC now owns 30,574 shares of the company’s stock valued at $148,000 after purchasing an additional 3,640 shares during the period. Finally, GAMMA Investing LLC bought a new stake in OptimizeRx during the first quarter valued at $33,000. 76.47% of the stock is currently owned by institutional investors.

OptimizeRx Stock Performance

Shares of OPRX opened at $10.01 on Thursday. OptimizeRx has a twelve month low of $3.78 and a twelve month high of $14.13. The firm’s 50 day moving average price is $8.14 and its two-hundred day moving average price is $6.31. The company has a debt-to-equity ratio of 0.29, a quick ratio of 3.23 and a current ratio of 3.23. The firm has a market cap of $185.11 million, a P/E ratio of -7.53 and a beta of 1.28.

OptimizeRx Company Profile

OptimizeRx Corporation, a digital health technology company, enables care-focused engagement between life sciences organizations, healthcare providers, and patients at critical junctures throughout the patient care journey. It offers various tech-enabled marketing solutions through its Artificial Intelligence-generated Dynamic Audience and Activation Platform, which enables customers to execute traditional marketing campaigns on its proprietary digital point-of-care network, as well as dynamic marketing campaigns that optimize audiences in real time to increase the value of treatment information for healthcare professionals and patients in response to clinical care events.